HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms among Integrase strand transfer Inhibitor-Naïve HIV-1 Patients from Cameroon.
The World Health Organization (WHO) has put forth recommendations for the use of Integrase (IN) strand transfers inhibitors (INSTIs) to be part of the first-line combination antiretroviral therapy (cART) regimen to treat HIV infections. The knowledge of pre-treatment drug resistance against INSTIs is still scarce in resource-limited settings. We characterised the integrase gene to identify resistance-associated mutations (RAMs) in 56 INSTI-naïve patient viral sequences from Cameroon. Study analysis used 37 sequences with fragment size ≥ 500bp or of good quality .The majority of the sequences were identified as CRF02_AG 54.% (n=20/37) and 45.9 % (n=17/37), other subtypes viral sequences includes (A, CRF36_cpx, F ,G and C). 18.9 % (n=7/37) of the sequences had RAMs, with only 5.4% (n=2/37) having major RAMs (Y143R/C/D/G and P145S), against INSTIs. Accessory RAMs were present in 8.1 % (n=3/37) of sequences, of which one sequence contained solely E157Q, another Q95K. One patient sequence had three accessory RAMs (G140E, E157Q, and G163R). We identified major RAMs to INSTIs, which might have a potential clinical impact to dolutegravir (DTG) roll out in resource-limited settings (RLS) including Cameroon. This is the first study to describe RAMs among INSTI naïve people living with HIV-1 (PLHIV-1) infected with CRF02_AG and other subtypes in Cameroon.